Last reviewed · How we verify
Keverprazan 14 days
Keverprazan is a direct renin inhibitor.
Keverprazan is a direct renin inhibitor. Used for Hypertension.
At a glance
| Generic name | Keverprazan 14 days |
|---|---|
| Also known as | Amoxicillin |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | direct renin inhibitor |
| Target | renin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Direct renin inhibitors are a class of drugs that block the action of renin, an enzyme involved in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance. By inhibiting renin, keverprazan reduces the production of angiotensin I and II, leading to vasodilation and decreased blood pressure.
Approved indications
- Hypertension
Common side effects
- dizziness
- cough
- hypotension
Key clinical trials
- Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection (PHASE3)
- Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment (PHASE4)
- Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori (NA)
- The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication (EARLY_PHASE1)
- Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment (PHASE3)
- Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: